{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009107","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.271455+00:00","generated_at":"2026-06-15T05:59:05.815728+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MaxCyte Q1 revenue $8.6M (-26% YoY), net loss $10.9M; cuts FY23 revenue growth guidance to 8-12%","bullets":["Total revenue $8.6M, down 26% YoY; core business revenue $7.8M, down 19%.","Net loss $10.9M vs $4.1M; EBITDA loss $12.2M vs $3.7M.","FY23 total revenue growth guidance lowered to 8%-12%; core revenue growth 5%-10%.","Two new SPL partnerships signed: Walking Fish Therapeutics (May) and Catamaran Bio (Jan).","Douglas J. Swirsky appointed CFO, effective immediately."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009107","json":"https://secwatch.observer/filing/0001558370-23-009107.json","markdown":"https://secwatch.observer/filing/0001558370-23-009107.md","text":"https://secwatch.observer/filing/0001558370-23-009107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/0001558370-23-009107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/mxct-20230510x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T05:59:05.815728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e264b7ae3d7ac9b3f5cef0bd25568707656089e1","claim":"MAXCYTE, INC. reported First quarter ended March 31, 2023 results: net income Net loss of $10.9 million.","evidence_excerpt":"Total revenue for the first quarter of 2023 was $8.6 million, compared to $11.6 million in the first quarter of 2022, representing a decline of 26%.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/0001558370-23-009107-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss of $10.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e264b7ae3d7ac9b3f5cef0bd25568707656089e1","claim":"MAXCYTE, INC. reported First quarter ended March 31, 2023 results: net income Net loss of $10.9 million.","evidence_excerpt":"First quarter 2023 net loss was $10.9 million compared to net loss of $4.1 million for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1287098/000155837023009107/0001558370-23-009107-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"First quarter ended March 31, 2023"},{"label":"Net income","value":"Net loss of $10.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}